None
Quote | Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)
Last: | $6.765 |
---|---|
Change Percent: | 1.73% |
Open: | $6.62 |
Close: | $6.65 |
High: | $6.7899 |
Low: | $6.62 |
Volume: | 14,207 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica’s President &...
2024-03-26 13:33:07 ET More on Verrica Pharmaceuticals Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript Verrica sues to keep unapproved cantharidin drugs off US market Verrica Pharmaceuticals stock gains on Walgreens distribution deal Seek...
Message Board Posts | Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)
Subject | By | Source | When |
---|---|---|---|
This is obviously not IHubbers buying. Broke | ErnieBilco | investorshub | 02/09/2023 3:43:24 PM |
But it's giving up its gains almost every | ErnieBilco | investorshub | 06/24/2022 10:26:16 PM |
$2 million buys. Something, something | wolfjr | investorshub | 06/24/2022 10:23:45 PM |
Ol Ernie just can't catch a break, bought | ErnieBilco | investorshub | 05/31/2022 9:48:59 PM |
Right or wrong I bought some $2.35 | ErnieBilco | investorshub | 05/25/2022 1:47:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company...
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica’s President &...
NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension WEST CHEST...